Tags

Type your tag names separated by a space and hit enter

Bronchoalveolar lavage fluid angiotensin-converting enzyme in interstitial lung diseases.
Am Rev Respir Dis. 1990 Jan; 141(1):117-23.AR

Abstract

In this study we evaluated the disease specificity of bronchoalveolar lavage fluid angiotensin-converting enzyme (BALF-ACE), its correlation with cellular constituents of bronchoalveolar lavage fluid (BALF), and for sarcoidosis, with other proposed markers of disease activity. Furthermore, the question of the clinical value of BALF-ACE determinations in in interstitial lung diseases or any of its subgroups was addressed. The study population consisted of 222 patients, 69 with biopsy proven sarcoidosis, 3 with hypersensitivity pneumonitis, 4 with acute histoplasmosis, 27 with idiopathic pulmonary fibrosis (IPF), 4 with rheumatoid arthritis-related interstitial fibrosis, 9 with pulmonary drug toxicity, 16 with pulmonary malignancies, 26 with other parenchymal lung disease entities, and 30 in whom the final diagnosis remained indeterminate. Elevated BALF-ACE concentrations were seen in all diagnostic categories. In sarcoidosis BALF-ACE levels correlated well with lavage lymphocyte counts (r = 0.49; p less than 0.0001), in contrast to IPF where they correlated well with lavage neutrophil counts (r = 0.51; p less than 0.007). The correlation of BALF-ACE and serum-ACE was significant. In sarcoidosis the mean BALF-ACE level was lower for patients with Stage-I chest roentgenographic patterns (0.664 U/L), compared to those with Stage II (1.112 U/L) and Stage III (1.083 U/L). It was concluded that elevated BALF-ACE levels are not specific for sarcoidosis. The correlations of BALF-ACE levels with different cellular constituents of BALF suggest a different cellular origin of BALF-ACE. In sarcoidosis BALF-ACE levels correlate well with other proposed markers of disease activity and seem to reflect pulmonary activity better than serum ACE.(

ABSTRACT

TRUNCATED AT 250 WORDS)

Authors+Show Affiliations

Thoracic Diseases Research Unit, Mayo Clinic/Foundation, Rochester, Minnesota 55905.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

2153351

Citation

Specks, U, et al. "Bronchoalveolar Lavage Fluid Angiotensin-converting Enzyme in Interstitial Lung Diseases." The American Review of Respiratory Disease, vol. 141, no. 1, 1990, pp. 117-23.
Specks U, Martin WJ, Rohrbach MS. Bronchoalveolar lavage fluid angiotensin-converting enzyme in interstitial lung diseases. Am Rev Respir Dis. 1990;141(1):117-23.
Specks, U., Martin, W. J., & Rohrbach, M. S. (1990). Bronchoalveolar lavage fluid angiotensin-converting enzyme in interstitial lung diseases. The American Review of Respiratory Disease, 141(1), 117-23.
Specks U, Martin WJ, Rohrbach MS. Bronchoalveolar Lavage Fluid Angiotensin-converting Enzyme in Interstitial Lung Diseases. Am Rev Respir Dis. 1990;141(1):117-23. PubMed PMID: 2153351.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Bronchoalveolar lavage fluid angiotensin-converting enzyme in interstitial lung diseases. AU - Specks,U, AU - Martin,W J,2nd AU - Rohrbach,M S, PY - 1990/1/1/pubmed PY - 1990/1/1/medline PY - 1990/1/1/entrez SP - 117 EP - 23 JF - The American review of respiratory disease JO - Am Rev Respir Dis VL - 141 IS - 1 N2 - In this study we evaluated the disease specificity of bronchoalveolar lavage fluid angiotensin-converting enzyme (BALF-ACE), its correlation with cellular constituents of bronchoalveolar lavage fluid (BALF), and for sarcoidosis, with other proposed markers of disease activity. Furthermore, the question of the clinical value of BALF-ACE determinations in in interstitial lung diseases or any of its subgroups was addressed. The study population consisted of 222 patients, 69 with biopsy proven sarcoidosis, 3 with hypersensitivity pneumonitis, 4 with acute histoplasmosis, 27 with idiopathic pulmonary fibrosis (IPF), 4 with rheumatoid arthritis-related interstitial fibrosis, 9 with pulmonary drug toxicity, 16 with pulmonary malignancies, 26 with other parenchymal lung disease entities, and 30 in whom the final diagnosis remained indeterminate. Elevated BALF-ACE concentrations were seen in all diagnostic categories. In sarcoidosis BALF-ACE levels correlated well with lavage lymphocyte counts (r = 0.49; p less than 0.0001), in contrast to IPF where they correlated well with lavage neutrophil counts (r = 0.51; p less than 0.007). The correlation of BALF-ACE and serum-ACE was significant. In sarcoidosis the mean BALF-ACE level was lower for patients with Stage-I chest roentgenographic patterns (0.664 U/L), compared to those with Stage II (1.112 U/L) and Stage III (1.083 U/L). It was concluded that elevated BALF-ACE levels are not specific for sarcoidosis. The correlations of BALF-ACE levels with different cellular constituents of BALF suggest a different cellular origin of BALF-ACE. In sarcoidosis BALF-ACE levels correlate well with other proposed markers of disease activity and seem to reflect pulmonary activity better than serum ACE.(ABSTRACT TRUNCATED AT 250 WORDS) SN - 0003-0805 UR - https://www.unboundmedicine.com/medline/citation/2153351/Bronchoalveolar_lavage_fluid_angiotensin_converting_enzyme_in_interstitial_lung_diseases_ DB - PRIME DP - Unbound Medicine ER -